Greenwich LifeSciences expands FLAMINGO-01 clinical trial into Europe

Greenwich LifeSciences (GLSI), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, provided the following update on the expansion of the clinical trial into Europe. The Company’s application to add an additional 11 sites in Spain, Germany, and Poland has been formally approved by EMA. The academic networks participating in each country are Geicam in Spain, Unicancer in France, GBG in Germany, GIM in Italy , and a network of Polish sites. With this additional approval, regulators have cleared the way to activate approximately 110-115 sites in Europe. Based on the interest of principal investigators at additional sites, the Company plans to submit applications to EMA regulators to add 5-10 additional sites in Ireland, Romania, and potentially other countries in Europe.